Why the study?
Does triple therapy (warfarin, aspirin, clopidogrel) affect mortality and bleeding compared to dual therapy (aspirin, clopidogrel) in patients with acute coronary syndrome?
Observational (n=5,706)
Yes
Does triple therapy (warfarin, aspirin, clopidogrel) affect mortality and bleeding compared to dual therapy (aspirin, clopidogrel) in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
In patients with acute coronary syndrome, adding warfarin to dual antiplatelet therapy increases major bleeding risk without a significant difference in 6-month mortality.
BACKGROUND: Although clopidogrel and aspirin (dual therapy, DT) are used for acute coronary syndrome (ACS), sometimes treatment with warfarin (triple therapy, TT) is required. AIM: To determine the incidence, complications, and outcomes of TT. METHODS: We analyzed Israeli surveys of ACS from 2000 to 2004. RESULTS: In these surveys, 5,706 (96%) were discharged alive from hospital. Post-ACS TT and DT were 76 patients (1.3%) and 2,661 patients (46.7%), respectively. The TT group was older with more prior cardiac disease. During hospitalization, the TT patients received more intravenous anticoagulant and antithrombotic agents, and had more heart failure, arrhythmias, ischemia, and major bleeding (2.6 vs. 0.6%, p=0.03). There were no differences in adjusted 30-day and 6-month mortality between the 2 groups. CONCLUSION: TT is feasible among ACS patients who require concomitant warfarin treatment.
No takes yet. Share an insight, caveat, or question.
Konstantino et al. (2005) conducted an observational in Acute Coronary Syndromes (n=5,706). Triple therapy (warfarin, clopidogrel, and aspirin) vs. Dual therapy (clopidogrel and aspirin) was evaluated on Major bleeding during hospitalization (p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: